This article is a correction to:
Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly
Sara Schaefer
Kasper Arthur Hettinga
James Cullor1,3
J. Bruce German
Bethany M. Henrick- 1Department of Food Science and Technology, Foods for Health Institute, University of California, Davis, Davis, CA, United States
- 2Wageningen University and Research, Wageningen, Netherlands
- 3School of Veterinary Medicine, University of California, Davis, Davis, CA, United States
- 4Food Science and Technology Department, University of Nebraska Lincoln, Lincoln, NE, United States
A Corrigendum on
Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly
by Schaefer, S., Hettinga, K. A., Cullor, J., German, J. B., and Henrick, B. M. (2018). Front. Immunol. 9:2254. doi: 10.3389/fimmu.2018.02254
In the original article, there was an error. The vaccine used in the trial is listed as Boostrix® (Merck Research Laboratory, Whitehouse Station, USA). The correct source of the DTaP vaccine used in this study is “Adacel® not “Boostrix®.”
A correction has been made to the Materials and Methods, Human Samples:
“Peripheral blood samples were collected at the time of enrollment (week 0) and serum was stored at −80°C until subsequent analysis. Participants were then randomized into two groups and provided with equal concentration and quantity of either dairy or soy supplement provided in powdered form in coded, single-serving bags. Both participants and researchers were blinded to the type of protein received. Participants were asked to consume two servings of protein powder (6 grams/packet) with 4 ounces of water or applesauce twice per day, with meals, for a total of 8 weeks. At week 4, participants were vaccinated with DTaP vaccine (Sanofi Pasteur Inc., Swiftwater PA). A 0.5-mL dose of Adacel® is formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 μg of inactivated PT, 8 μg of FHA, and 2.5 μg of pertactin (69 kiloDalton outer membrane protein). Each 0.5-mL dose contains aluminum hydroxide as adjuvant (not more than 0.39 mg aluminum by assay), 4.5 mg of sodium chloride, ≤ 100 μg of residual formaldehyde, and ≤ 100 μg of polysorbate 80 (Tween 80). A second blood draw was obtained 4 weeks after vaccination (week 8) and serum collected for DTaP antibody analysis. The design and participant progression through the study is presented in Figure 1.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: nutritional supplementation, dairy proteins, immune response, vaccines, UV-C treatment
Citation: Schaefer S, Hettinga KA, Cullor J, German JB and Henrick BM (2019) Corrigendum: Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly. Front. Immunol. 10:427. doi: 10.3389/fimmu.2019.00427
Received: 04 February 2019; Accepted: 18 February 2019;
Published: 18 March 2019.
Edited by:
Pinyi Lu, Biotechnology HPC Software Applications Institute (BHSAI), United StatesReviewed by:
Zhuoran Yin, Brigham and Women's Hospital, Harvard Medical School, United StatesFrançois J. M. A. Meurens, INRA UMR703 Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation de Nantes-Atlantique, France
Copyright © 2019 Schaefer, Hettinga, Cullor, German and Henrick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sara Schaefer, seschaefer@ucdavis.edu